Safety and Efficacy of Neostigmine Against Residual Neuromuscular Blockade in Pediatric Patients During Recovery From General Anesthesia: A Retrospective Cohort Study

Hongyang Chen, Lei Yang, Zining Wang, Di Yang, Weiyi Zhang, Tao ZhuResearch 2021 · DOI

Introduction

Residual neuromuscular blockade (RNMB) remains a significant concern in clinical anesthesia. It occurs when muscle relaxants used during surgery are not fully cleared or reversed by the time a patient emerges from anesthesia. Pediatric patients are particularly vulnerable to RNMB due to their lower physiological tolerance for hypoxia and higher risk of respiratory complications, such as airway collapse or failure during the recovery period.

Neostigmine, an acetylcholinesterase inhibitor, is commonly administered to antagonize neuromuscular block. However, its routine use in children is a subject of ongoing debate. Some evidence suggests that "blind" administration—giving the drug based on clinical signs rather than objective monitoring—may not improve safety and could potentially lead to adverse effects. This study aimed to evaluate the safety and efficacy of routine neostigmine use in a large pediatric cohort in a real-world hospital setting.

Methods

This retrospective cohort study was conducted at West China Hospital, Sichuan University, reviewing records from January 2018 to September 2019. The study included pediatric patients undergoing general anesthesia where muscle relaxants were used.

To minimize the impact of confounding variables inherent in retrospective data, the researchers employed 1:1 Propensity Score Matching (PSM). Patients were matched based on age, weight, ASA physical status grade, airway device type, and surgery duration, effectively mimicking the balance of a randomized controlled trial. The primary outcomes measured were the lowest pulse oxygen saturation (SpO2) after extubation and the incidence of hypoxemia (SpO2 < 90%). Secondary outcomes included in-hospital mortality, length of hospital stay, and total medical expenses.

Figure 1: Flowchart of the patient selection and propensity score matching process.

Results

The initial screening identified 9,357 pediatric records. After applying exclusion criteria—such as missing outcome data or cases where no muscle relaxants were administered—and performing propensity score matching, the final analysis focused on 1,820 patients (910 in the neostigmine group and 910 in the control group).

Statistical analysis revealed no significant differences between the two groups across all primary and secondary outcomes:

  • Oxygenation: The mean lowest SpO2 was 98.90% in the neostigmine group compared to 98.78% in the control group (p = 0.43).
  • Hypoxemia: The incidence of hypoxemia was 2.53% for those receiving neostigmine versus 2.31% for those who did not (p = 0.76).
  • Mortality: There was one death in the neostigmine group and none in the control group, a difference that was not statistically significant (p = 0.32).
  • Resource Utilization: No significant differences were found in the length of hospital stay (5.66 vs. 5.88 days, p = 0.46) or medical expenses (~17,967 vs. ~17,406 yuan, p = 0.55).

Subgroup analyses based on age (<2 years, 3-5 years, and >6 years) and neostigmine dosage (low dose ≤ 0.02 mg/kg vs. high dose > 0.02 mg/kg) also failed to show any significant associations with clinical outcomes.

Discussion

The findings suggest that routine, non-monitored administration of neostigmine does not provide a clear clinical advantage in preventing post-extubation respiratory complications in children. Several factors may contribute to this "clinical neutrality."

First, there is a notable "monitoring gap." In this study setting, recovery was assessed using clinical signs (such as head lifting) rather than objective Train-of-Four (TOF) monitoring. Clinical signs are often insensitive to mild but clinically relevant levels of RNMB. Second, neostigmine exhibits a "ceiling effect," where increasing the dose beyond a certain point does not enhance reversal but may increase side effects like bradycardia or increased airway secretions.

The lack of difference between groups might indicate that many children recover sufficient neuromuscular function spontaneously, or that the timing and dosing of neostigmine in routine practice are not optimized to provide additional safety benefits without objective data to guide administration.

Conclusion

In this large-scale retrospective study, the application of neostigmine to reverse neuromuscular blockade was not associated with improved respiratory outcomes, reduced mortality, or shorter hospital stays in pediatric patients. While neostigmine appears safe, its routine efficacy without objective monitoring remains unproven. These results highlight the need for prospective, randomized controlled trials that incorporate objective neuromuscular monitoring to establish clearer guidelines for pediatric anesthesia recovery.

Summary updated

Abstract

Abstract Introduction: with the wide application of muscle relaxants in clinic, the anesthesiologists pay more and more attention to the residual neuromuscular block. While the pediatric patients have poor tolerance to hypoxia, compared to adult patients, the residual neuromuscular block do more harm to them in recovery period of anesthesia, such as respiratory failure, hypoxia, asphyxia and even death. In order to reduce the risk of the residual neuromuscular block complications, we design the following regression cohort study to conform the safety and effectiveness of routine use of neostigmine after operation. Methods: This study was a retrospective cohort study (ChiCTR1900028048), approved by the ethics committee of West China Hospital, Sichuan University. We reviewed pediatric patients who received surgical treatment in West China Hospital, Sichuan University from January 1, 2018 to September 30, 2019.The exposure factor was the use of neostigmine during the period of anesthesia recovery. Inclusion criteria: the pediatric surgery department patients who underwent general anesthesia in West China Hospital, Sichuan University. Exclusion criteria: cases without medical electronic records; Cases with missing outcome data; No muscle relaxants were used during general anesthesia. The outcomes included: lowest pulse oxygen saturation after endotracheal extubation; incidence of hypoxemia after endotracheal extubation; in-hospital mortality; length of hospital stay; medical expenses. IBM SPSS Statistics 23.0 software was used for statistical analysis.1:1 propensity score matching was used to eliminate the influence of confounding factors. For continuous variables, student t test was used . For categorical variables, the chi-square test was used. The results were considered statistically significant, if p value &lt; 0.05. Subgroup analysis was performed according to the age (&lt;2 years / 3-5 years or &gt;6 years) and the dose of neostigmine (low dose group &lt;=0.02mg/kg or high dose group &gt;0.02mg/kg). Results: A total of 4358 pediatric patients were included. After 1:1 propensity score matching, 1820 pediatric patients were included for statistical analysis. In-hospital mortality (1/910 vs 0/910, p = 0.32), lowest pulse oxygen saturation after endotracheal extubation (98.90±3.05 vs 98.78±3.48, p = 0.43), incidence of hypoxemia after endotracheal extubation (23/910 vs 21/910, p=0.76), length of hospital stay (5.66±6.11 vs 5.88±6.59, p= 0.46), and medical expenses (17967.04±21325.86 vs 17406.96±18358.17, p=0.55) showed no significantly statistical differences between the pediatric patients with or without neostigmine application to reverse the neuromuscular blockade during anesthesia recovery. Subgroup analysis found no significant associations between the outcomes and age of the patients or the dose of neostigmine. Conclusion: For pediatric patients, neostigmine application to reverse the neuromuscular blockade was not significantly associated with in hospital mortality, lowest pulse oxygen saturation after endotracheal extubation, incidence of hypoxemia after endotracheal extubation, medical expenses, or length of hospital stay. However, as some confounding factors cannot be eliminated in this retrospective study, the results of this study are needed to be confirmed by future prospective studies. Trial registration: Medical records based study for the recovery effect of antagonitst of muscle relaxant in pediatric patients, ChiCTR1900028048, Registered 8 September 2019, https://www.chictr.org.cn/showproj.aspx?proj=46686
BibTeX
@inproceedings{chen2021safety,
  author = {Hongyang Chen and Lei Yang and Zining Wang and Di Yang and Weiyi Zhang and Tao Zhu},
  title = {{Safety and Efficacy of Neostigmine Against Residual Neuromuscular Blockade in Pediatric Patients During Recovery From General Anesthesia: A Retrospective Cohort Study}},
  booktitle = {Research},
  year = {2021},
  doi = {10.21203/rs.3.rs-967875/v1},
}
Figure